LVTX LAVA Therapeutics
- 1.110
- -0.090-7.50%
- 1.140
- +0.030+2.70%
LAVA Therapeutics News
Leerink Partners Downgrades LAVA Therapeutics to Market Perform, Lowers Price Target to $2
Hold Rating on LAVA Therapeutics Amid Uncertainty and Program Discontinuation
Leerink Partners Downgrades LAVA Therapeutics(LVTX.US) to Hold Rating, Announces Target Price $2
Lava Therapeutics Price Target Maintained With a $6.00/Share by JMP Securities
LAVA Therapeutics Analyst Ratings
JMP Securities Downgrades LAVA Therapeutics(LVTX.US) to Hold Rating
Lava Therapeutics Price Target Maintained With a $6.00/Share by JMP Securities
Jefferies Maintains LAVA Therapeutics(LVTX.US) With Buy Rating, Maintains Target Price $6
LAVA Therapeutics: Promising Clinical Trials and Strategic Partnerships Bolster Buy Rating
JMP Securities Maintains LAVA Therapeutics(LVTX.US) With Buy Rating, Maintains Target Price $6
Buy Rating Affirmed: LAVA Therapeutics' Financial Stability and Promising Clinical Pipeline
LAVA Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Aldeyra Therapeutics (ALDX), LAVA Therapeutics (LVTX) and Crinetics Pharmaceuticals (CRNX)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Generation Bio (GBIO), LAVA Therapeutics (LVTX) and Aura Biosciences Inc (AURA)
Analysts Offer Insights on Healthcare Companies: LAVA Therapeutics (LVTX), Acumen Pharmaceuticals (ABOS) and Advanced Medical Solutions (GB:AMS)
Buy Rating Affirmed for LAVA Therapeutics Amid Promising T-Cell Cancer Therapy Trials and Strong Financials
Strong Buy Rating for LAVA Therapeutics on Promising Clinical and Financial Outlook
LAVA Therapeutics Analyst Ratings
Analysts Are Bullish on Top Healthcare Stocks: AdaptHealth (AHCO), LAVA Therapeutics (LVTX)
Strong Buy Rating for LAVA Therapeutics Amid Strategic Partnerships and Promising Clinical Advancements
No Data